Department of Nephrology and Hypertension, University Medical Center, Utrecht, The Netherlands.
Am J Hypertens. 2010 Jul;23(7):802-8. doi: 10.1038/ajh.2010.48. Epub 2010 Apr 1.
In fawn-hooded hypertensive (FHH) rats, a model of hypertension, impaired preglomerular resistance, hyperfiltration, and progressive renal injury, we recently observed that supporting perinatal nitric oxide (NO) availability with the NO donor molsidomine persistently reduced blood pressure (BP) and ameliorated renal injury in male and female offspring. However, beneficial effects of perinatal molsidomine treatment were more pronounced in female than in male FHH rats.
To evaluate whether such protective effects could also be achieved with micronutrients, and whether the gender-dependent differences could be confirmed, we tested perinatal exposure to the micronutrients L-arginine, taurine, vitamin C, and vitamin E (ATCE) in FHH rats. Perinatal micronutrients increased urinary NO metabolite, sodium and potassium excretion only at 4 weeks of age, i.e., at the end of treatment.
From 12 weeks onwards, control males had a significantly higher systolic BP (SBP) than females (P < 0.01); however after perinatal micronutrients, this difference was no longer present, indicating a pronounced antihypertensive effect of perinatal micronutrients in males (interaction P < 0.001). Development of proteinuria was attenuated by perinatal micronutrients in males and females. However, only females showed reduced glomerular filtration rate, filtration fraction, and glomerulosclerosis (GS) after perinatal micronutrients.
In sum, perinatal micronutrients that enhance NO availability ameliorated development of hypertension and proteinuria in FHH rats. Antihypertensive effects were more pronounced in male FHH offspring, whereas renal protective effects were more pronounced in female FHH offspring. Mechanisms underlying gender-specific consequences of perinatal micronutrients require further study.
在小鹿色高血压(FHH)大鼠中,一种高血压模型,我们最近观察到,支持围产期一氧化氮(NO)可用性的 NO 供体吗多明可持久降低血压(BP)并改善雄性和雌性后代的肾损伤。然而,围产期吗多明治疗的有益效果在雌性 FHH 大鼠中比在雄性 FHH 大鼠中更为明显。
为了评估围产期暴露于微量营养素是否也能达到这种保护作用,以及是否能证实性别依赖性差异,我们在 FHH 大鼠中测试了围产期暴露于微量营养素 L-精氨酸、牛磺酸、维生素 C 和维生素 E(ATCE)。围产期微量营养素仅在 4 周龄时增加尿 NO 代谢物、钠和钾排泄,即在治疗结束时。
从 12 周开始,雄性对照的收缩压(SBP)显著高于雌性(P < 0.01);然而,在围产期接受微量营养素后,这种差异不再存在,表明围产期微量营养素对雄性具有明显的降压作用(交互 P < 0.001)。围产期微量营养素可减轻雄性和雌性蛋白尿的发生。然而,只有雌性在接受围产期微量营养素后肾小球滤过率、滤过分数和肾小球硬化(GS)降低。
总之,增强 NO 可用性的围产期微量营养素可改善 FHH 大鼠高血压和蛋白尿的发展。在雄性 FHH 后代中,降压作用更为明显,而在雌性 FHH 后代中,肾保护作用更为明显。围产期微量营养素性别特异性后果的机制需要进一步研究。